Exbio — Research products — Antibodies — CD and related antigens — Anti-Hu CD340 Purified

Anti-Hu CD340 Purified

Anti-Hu CD340 Purified
Regulatory status
RUO
Antigen
CD340
Clone
24D2
Format
Purified
Reactivity
Human
Application
FC (QC tested), ICC
Variant
0.1 mg
11-832-C100
In stock
170.00 USD
Variant
0.1 mg
11-261-C100
In stock
170.00 USD
Contact distributor
Product details
References
Isotype
Mouse IgG1
Specificity
The mouse monoclonal antibody 24D2 recognizes an extracellular epitope of human CD340 (HER-2), a type I transmembrane protein expressed by mesenchymal stem cells, B-lymphoblastic leukemia cells, subsets of C-ALL blasts, and and various types of carcinomas.
Workshop
HLDA X
Application
FC (QC tested), ICC
Reactivity
Human
Immunogen
NIH-3T3/huCD340 cells
Other names
ERBB2, NEU, NGL, HER2, TKR1, MLN 19
Concentration
1 mg/ml
Preparation
Purified by protein-A affinity chromatography
Formulation
Phosphate buffered saline (PBS) solution with 15 mM sodium azide
Storage and handling
Store at 2-8°C. Do not freeze. Do not use after expiration date stamped on vial label.
Exbio licence note
The product is intended For Research Use Only. Diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s.

General references:

Arora P, Cuevas BD, Russo A, Johnson GL, Trejo J: Persistent transactivation of EGFR and ErbB2/HER2 by protease-activated receptor-1 promotes breast carcinoma cell invasion. Oncogene. 2008 Mar 31
PubMed
Northey JJ, Chmielecki J, Ngan E, Russo C, Annis MG, Muller WJ, Siegel PM: Northey JJ, Chmielecki J, Ngan E, Russo C, Annis MG, Muller WJ, Siegel PM: Signaling through ShcA is required for TGF-{beta} and Neu/ErbB-2 induced breast cancer cell motility and invasion. Mol Cell Biol. 2008 Mar 10
PubMed
Yuan W, Wang W, Cui B, Su T, Ge Y, Jiang L, Zhou W, Ning G: Overexpression of ERBB-2 was more frequently detected in malignant than benign pheochromocytomas by multiplex ligation-dependent probe amplification and immunohistochemistry. Endocr Relat Cancer. 2008 Mar;15(1):343-50.
PubMed
Hicks DG, Kulkarni S: HER2+ breast cancer: review of biologic relevance and optimal use of diagnostic tools. Am J Clin Pathol. 2008 Feb;129(2):263-73.
PubMed
Dowsett M, Hanna WM, Kockx M, Penault-Llorca F, Rüschoff J, Gutjahr T, Habben K, van de Vijver MJ: Standardization of HER2 testing: results of an international proficiency-testing ring study. Mod Pathol. 2007 May;20(5):584-91.
PubMed
Koeppen HK, Wright BD, Burt AD, Quirke P, McNicol AM, Dybdal NO, Sliwkowski MX, Hillan KJ: Overexpression of HER2/neu in solid tumours: an immunohistochemical survey. Histopathology. 2001 Feb;38(2):96-104.
PubMed

Product specific references:

Bühring HJ, Sures I, Jallal B, Weiss FU, Busch FW, Ludwig WD, Handgretinger R, Waller HD, Ullrich A: The receptor tyrosine kinase p185HER2 is expressed on a subset of B-lymphoid blasts from patients with acute lymphoblastic leukemia and chronic myelogenous leukemia. Blood. 1995 Sep 1;86(5):1916-23.
PubMed
Bühring HJ, Battula VL, Treml S, Schewe B, Kanz L, Vogel W: Novel markers for the prospective isolation of human MSC. Ann N Y Acad Sci. 2007 Jun;1106:262-71.
PubMed
Tran T, Diniz MO, Dransart E, Gey A, Merillon N, Lone YC, Godefroy S, Sibley C, Ferreira LC, Medioni J, Oudard S, Johannes L, Tartour E: A Therapeutic Her2/neu Vaccine Targeting Dendritic Cells Preferentially Inhibits the Growth of Low Her2/neu-Expressing Tumor in HLA-A2 Transgenic Mice. Clin Cancer Res. 2016 Aug 15;22(16):4133-44.
PubMed
Bailey TA, Luan H, Tom E, Bielecki TA, Mohapatra B, Ahmad G, George M, Kelly DL, Natarajan A, Raja SM, Band V, Band H: A kinase inhibitor screen reveals protein kinase C-dependent endocytic recycling of ErbB2 in breast cancer cells. J Biol Chem. 2014 Oct 31;289(44):30443-58.
PubMed
Variant
0.1 mg
11-832-C100
In stock
170.00 USD
Variant
0.1 mg
11-261-C100
In stock
170.00 USD
Contact distributor
Datasheet download
SDS download
Bulk requests
Technical support for this product